ClinicalTrials.gov
ClinicalTrials.gov Menu

AZD1419 Ph2a Study (INCONTRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02898662
Recruitment Status : Completed
First Posted : September 13, 2016
Last Update Posted : October 10, 2018
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
Ph2a study planned to be run at approximately 16-18 sites in 4 EU countries (Denmark, Hungary, Poland and Sweden) enrolling approximately 170 patients to ensure 70 randomized patients with eosinophilic, moderate to severe asthma. The patients will receive 13 once weekly inhaled doses of the study drug. Treatment is initiated on top of their ICS/LABA controller medication, which is then tapered down and withdrawn during a period of 3 weeks and during the last 3 weeks of treatment the study drug is given as monotherapy. SABA is used as reliever medication during the whole study period. Primary endpoint is Loss of asthma control. When the endpoint is met, patients will resume their ICS/LABA, will be followed for an additional 4 weeks and will thereafter discontinue the study.

Condition or disease Intervention/treatment Phase
Asthma Drug: AZD1419 Drug: Placebo Phase 2

Detailed Description:

Ph2a study planned to be run in approximately 16-18 sites in 4 EU countries (Denmark, Hungary, Poland and Sweden) enrolling approximately 170 patients to ensure 70 randomized patients with eosinophilic, moderate to severe asthma.

The study has a withdrawal design.The patients will receive 13 once weekly inhaled doses of the study drug (AZD1419 or placebo). Treatment is initiated with 6 doses of the study drug on top of their ICS/LABA controller medication. Prior to the 7th dose of the study drug the LABA is withdrawn. The following 3 doses are given when ICS is tapered down. Dose 7 is given on top of 100% of their ICS, dose 8 is given on top of 50% of the ICS dose, which is then tapered down to 25% the following week and withdrawn completely prior to dose 10 of the study drug. During the last 3 weeks of treatment (ie last 4 doses), the study drug is given as monotherapy. SABA is used as reliever medication during the whole study period. Primary endpoint is Loss of asthma control, defined as any of the following criteria: a) An increase of ACQ-5 to 1.5 or more b) A reduction of 30% or more in morning peak expiratory flow (PEF) from baseline on 2 consecutive days c) At least six additional reliever inhalations of SABA in a 24-hour period relative to baseline on 2 consecutive days and d) An exacerbation requiring systemic corticosteroids

When the endpoint is met, patients will resume their regular ICS/LABA controller medication and will be followed for an additional 4 weeks, when they do an Early Discontinuation (ED) Visit and will thereafter leave the study. For patients not loosing their asthma control, the full Observational period is up to week 52, when they will do an End of Treatment Visit (EOT). Study procedures are the same on ED and EOT Visits.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma
Actual Study Start Date : October 12, 2016
Actual Primary Completion Date : September 25, 2018
Actual Study Completion Date : September 25, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: AZD1419
Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
Drug: AZD1419
Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events

Placebo Comparator: Placebo
Matching placebo
Drug: Placebo
Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events




Primary Outcome Measures :
  1. Time to Loss of control [ Time Frame: Up to 52 weeks ]

    Loss of asthma control is defined as any of the following:

    1. An increase of ACQ-5 to 1.5 or more
    2. A reduction of 30% or more in morning peak expiratory flow (PEF) from baseline on 2 consecutive days
    3. At least six additional reliever inhalations of SABA in a 24-hour period relative to baseline on 2 consecutive days
    4. An exacerbation requiring systemic corticosteroids


Secondary Outcome Measures :
  1. Proportion of patients who experience loss of asthma control [ Time Frame: Up to 52 weeks ]

    Loss of asthma control is defined as any of the following:

    1. An increase of ACQ-5 to 1.5 or more
    2. A reduction of 30% or more in morning peak expiratory flow (PEF) from baseline on 2 consecutive days
    3. At least six additional reliever inhalations of SABA in a 24-hour period relative to baseline on 2 consecutive days
    4. An exacerbation requiring systemic corticosteroids

  2. Changes over the course of the study in ACQ-5 [ Time Frame: Up to 52 weeks ]
    Weekly assessment of Asthma questionaire

  3. Changes over the course of the study in asthma daily diary score [ Time Frame: Up to 52 weeks ]
    Asthma Daily Diary recordings (twice daily) in ePRO device

  4. Changes over the course of the study in number of moderate and severe exacerbations [ Time Frame: Up to 52 weeks ]
  5. Changes over the course of the study in the use of reliever bronchodilator (short-acting beta-agonist SABA) [ Time Frame: Up to 52 weeks ]
    Use of reliever medication recorded twice daily in the ePRO device

  6. Changes over the course of the study in pre- and post-bronchodilator FEV1 [ Time Frame: Up to 52 weeks ]
  7. Changes over the course of the study in PEF [ Time Frame: Up to 52 weeks ]
    PEF recordings twice daily captured in the ePRO device.

  8. Changes over the course of the study inFeNO [ Time Frame: Up to 52 weeks ]
    Assessed weekly in the clinic as well as captured by the patient every other day in a handheld device

  9. Adverse events, vital signs, ECG and laboratory parameters [ Time Frame: Up to 52 weeks ]
  10. Weekly peak expiratory flow rate (PEFR) [ Time Frame: Up to 52 weeks ]
  11. Lung diffusion capacity (DLco) [ Time Frame: Up to 52 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients 18 years and above
  • Physician-diagnosed asthma requiring treatment with ICS and a long-acting beta agonist (LABA). Patients must have taken ICS plus LABA controller medication for at least 3 months prior to screening
  • Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥50% predicted
  • Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception
  • Male patients must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) from the first dose of the IMP and until 1 month after the last dose of the IMP to prevent pregnancy in a partner
  • Blood eosinophil levels ≥ 250 cells/μL at screening OR a history of blood eosinophil levels ≥ 250 cells/μL at any time in the preceding 2 years AND blood eosinophil levels ≥ 150 cells /μL at screening. The eosinophilia must be believed to be due to asthma and not have other known causes, e.g. helminth infection
  • ACQ-5 score ≤1.5 at screening
  • ACQ-5 score ≤0.75 at randomization
  • Documentation of any of the following within 5 years prior to Visit 1:

    • Proof of post-bronchodilator reversibility in FEV1 of ≥12% and ≥200 mL
    • Proof of a positive response to a methacholine or histamine challenge (a decrease in FEV1 by 20% [PC20] at ≤8 mg/mL)
    • Proof of positive response to mannitol challenge (a decrease in FEV1 by 15% [PD15] at ≤635 mg or a >10% decrease in FEV1 between consecutive doses)
    • Proof of diurnal variability in PEF >20% over the course of 24 hours in at least 4 out of 7 consecutive days If historical documentation is not available, proof of reversibility or a positive response to a methacholine, histamine or mannitol challenge or diurnal variation must be demonstrated according to above and documented during Visit 1

Exclusion Criteria:

  • Clinically significant lung disease other than asthma (eg, chronic obstructive pulmonary disease, cystic fibrosis, allergic bronchopulmonary aspergillosis, active tuberculosis).
  • History of autoimmune disease including but not limited to Wegener's granulomatosis, system lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, multiple sclerosis, autoimmune thrombocytopenia, primary biliary cirrhosis or any other autoimmune disease considered clinically relevant by the investigator
  • Ongoing allergen immunotherapy or plans to begin such therapy during the study period
  • DLco ≤ 60% of the lower limit of normal
  • Breast feeding, pregnancy or intention to become pregnant during the course of the study
  • Changes in chest X-ray suggesting clinically significant parenchymal disease other than asthma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02898662


Locations
Denmark
Research Site
Hvidovre, Denmark, 2650
Research Site
København NV, Denmark, 2400
Research Site
Naestved, Denmark
Research Site
Odense C, Denmark, 5000
Hungary
Research Site
Balassagyarmat, Hungary, 2660
Research Site
Edelény, Hungary, 3780
Research Site
Farkasgyepü, Hungary, 8582
Research Site
Miskolc, Hungary, 3529
Research Site
Törökbálint, Hungary, 2045
Poland
Research Site
Lubin, Poland, 59-300
Research Site
Łódź, Poland, 90-153
Sweden
Research Site
Linköping, Sweden, 587 58
Research Site
Lund, Sweden, 221 85
Research Site
Stockholm, Sweden, 141 86
Sponsors and Collaborators
AstraZeneca

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02898662     History of Changes
Other Study ID Numbers: D2500C00003
First Posted: September 13, 2016    Key Record Dates
Last Update Posted: October 10, 2018
Last Verified: October 2018

Keywords provided by AstraZeneca:
inhaled
TLR9 agonist
withdrawal design
loss of control

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases